Premium
Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer’s disease: A mass spectrometry study
Author(s) -
Talib Leda Leme,
Costa Alana Caroline,
Joaquim Helena Passarelli Giroud,
Forlenza Orestes Vicente,
Gattaz Wagner Farid
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.043519
Subject(s) - sphingomyelin , metabolomics , dementia , pathophysiology , medicine , cognitive impairment , metabolite , alzheimer's disease , disease , endocrinology , psychology , chemistry , cholesterol , chromatography
Background Membrane metabolites are important mediators of neuronal function. The metabolomic profile of patients with Alzheimer’s disease (AD) and mild cognitive impairment (MCI) may suggest potential diagnostic biomarkers and provide information on the pathophysiology of dementia. Method We investigated the metabolomic profile of 79 older adults with primary cognitive impairment (34 patients with AD and 20 with MCI) and 25 physically and cognitively healthy elders (controls). We quantified plasma metabolites including membrane phospholipids, sphingomyelins, and acylcarnitines using the AbsoluteIDQ ® p180 followed by flow injection analysis coupled with mass spectrometry. Result A cluster analysis revealed that a combination of acylcarnitines (C12‐DC, C12) and phosphatidylcholine (PC aa C26:0) could differentiate the patients according to diagnostic groups. As a general trend, phosphatidylcholines, acylcarnitines and sphingomyelins levels were lower in AD and MCI subjects compared to healthy controls, and this decrease was even more significant in MCI. The concentration of lysophospholipids was higher in AD and decreased in MCI, as compared to controls. Conclusion Future studies should combine metabolomic profiles with other biomarkers to identify diagnostic groups.